Core Viewpoint - The news summarizes important announcements from various companies, highlighting significant developments in their operations and financial performance. Company Announcements - Tianfeng Securities received a notice from the China Securities Regulatory Commission regarding a case of information disclosure violation related to Fujian Yong'an Forestry Group, and the company will cooperate with the investigation [3] - Southwest Securities plans to raise no more than 6 billion yuan through a private placement to supplement its capital and optimize its capital structure [4] - Qiaoyin Co. has terminated its investment in the artificial intelligence industry headquarters project due to changes in cooperation conditions, with a planned investment of no more than 1 billion yuan [5] - Zongshen Power is planning a major asset swap with Longxin General, aiming to resolve competition issues and promote clearer business development [6] - Laimei Pharmaceutical's selected products for national centralized procurement are expected to generate 106 million yuan in sales for 2024, accounting for 13.35% of the company's revenue [7] Performance Reports - Huayin Technology reported a net profit of 313 million yuan for 2025, a decrease of 24.28%, with revenue of 1.251 billion yuan, up 9.83% [9] - Youlide announced a net profit of 152 million yuan for 2025, down 16.88%, with revenue of 1.221 billion yuan, up 7.99% [10][11] - Fudan Microelectronics reported a net profit of 232 million yuan for 2025, a decline of 59.42%, with revenue of 3.982 billion yuan, up 10.92% [12] - Hanzhong Precision reported a net profit of 470 million yuan for 2025, down 45.54%, with revenue of 2.928 billion yuan, a decrease of 20.32% [13] Shareholding Changes - Gaomei Co.'s controlling shareholder and several directors plan to reduce their holdings by up to 3.19% of the company's shares [15] - Guanghuan New Network's controlling shareholder intends to reduce its stake by up to 3% [16] - ST Yigou's shareholder plans to reduce its holdings by up to 2.5% [17] - Juguang Technology's shareholders plan to collectively reduce their holdings by up to 2.3339% [18] - Xiandai Jidian's shareholder intends to reduce its stake by up to 2.05% [19] - Zhejing Pharmaceutical's shareholders plan to reduce their holdings by up to 1.0385% [21] Contract Signings - China Nuclear Construction signed contracts worth 3.393 billion yuan in January, with total revenue of 7.69 billion yuan [23] - China Chemical signed contracts totaling 36.925 billion yuan in January, including significant contracts over 500 million yuan [24]

Group 1 - The company announced the use of idle funds to subscribe to notes linked to a fund issued by Essence Global Investment Limited and China Rock Fund, with a total scale of approximately HKD 400 million, aimed at enhancing capital returns and ensuring liquidity [1] - Following the announcement, the company's stock price increased by 3.76% on the first trading day (February 9), but experienced volatility in subsequent days [1] - Over the five trading days from February 9 to February 13, the stock price showed fluctuations, with a maximum range of 10.16%, indicating mixed market sentiment [1] Group 2 - According to the Q2 2025 financial report, the company recorded a quarterly revenue of approximately CNY 159 million, a quarter-on-quarter increase of 76.7%, and a net profit of CNY 52 million, with a gross margin of 84% [2] - The generic drug business accounted for 98% of the revenue, with centralized procurement products contributing significantly to the growth [2] - Although the financial report data is robust, its release in October 2025 means it has limited direct impact on the current stock price [2]

Core Viewpoint - Zhongheng Group (600252.SH) announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd. (referred to as "Laimei Pharmaceutical"), and its wholly-owned subsidiary, Hunan Kangyuan Pharmaceutical Co., Ltd. (referred to as "Hunan Kangyuan"), participated in the national centralized procurement for drugs whose agreements have expired, indicating potential selection for procurement which could enhance sales and market expansion [1] Group 1 - Laimei Pharmaceutical and Hunan Kangyuan participated in the bidding organized by the National Centralized Procurement Office for drugs with expired agreements [1] - The procurement is led by a coalition of provinces and regions, including Jiangsu, Henan, and Guangdong, focusing on products from the first eight batches of the national centralized procurement [1] - If procurement agreements are signed and implemented, it will positively impact the sales and brand influence of the selected products, contributing to the long-term development of the company [1]

Recent Events - The company announced on February 11, 2026, that its wholly-owned subsidiary, Chengdu Saintno Biological Pharmaceutical Co., Ltd., is participating in the national organized procurement of medicines, with multiple products (such as Acetate Octreotide Injection and Thymosin Alpha 1 Injection) expected to be selected. The results of the selection are anticipated to be officially implemented by the end of March 2026, with the procurement cycle lasting until the end of 2028. This event may impact future sales scale and market share [2]. Performance and Operations - The company released a profit forecast on January 16, 2026, indicating a significant year-on-year increase in net profit attributable to the owners of the parent company. However, specific financial data will be confirmed in the subsequent audited annual report, the release date of which has not yet been announced. Attention should be paid to official communications from the company [3].

Group 1 - The A-share market experienced a decline on the last trading day of the Year of the Snake, with major indices falling over 1% and total trading volume below 2 trillion yuan [1] - The military industry sector saw gains due to international tensions, while sectors like photovoltaic equipment and steel faced significant declines [1] - Analysts suggest that investors should "hold stocks over the holiday" as a new market trend is expected post-holiday [1] Group 2 - The China Securities Regulatory Commission (CSRC) has imposed penalties on Tianfeng Securities for illegal financing and information disclosure violations related to the Wuhan Contemporary Technology Industry Group [2] - Tianfeng Securities and its former executives face fines totaling 34.8 million yuan, with lifetime market bans for key individuals [2] - The Shanghai and Shenzhen Stock Exchanges have issued notifications to standardize investor education and compliance requirements for bond repurchase transactions [2] Group 3 - TrendForce predicts that HBM4 validation will be completed by Q2 2026, driven by increasing GPU demand from AI infrastructure expansion [3] - The global DRAM/NAND Flash market is expected to reach $75.51 billion by Q4 2025, with a quarter-on-quarter growth of 29.2% [4] - The lithium carbonate price surged in January 2026, with battery-grade prices rising by 28.15% to 152,500 yuan per ton [4] Group 4 - The Chinese gaming market reported actual sales revenue of 32.468 billion yuan in January 2026, reflecting a year-on-year growth of 4.47% [5] - Huawei's former multimedia technology department head was arrested for bribery, highlighting internal compliance issues [5] - Luxury brands LV, Dior, and Tiffany were fined over 36 billion won in South Korea for customer information leaks [6] Group 5 - Pinduoduo established two new affiliated companies in Shanghai with a combined registered capital of 15 billion yuan, indicating potential supply chain upgrades [7] - Haoyou Engineering won a $4 billion contract for the NFPS COMP5 project in Qatar, with the company's share exceeding $800 million [8] - Qiaoyin Co. terminated its artificial intelligence headquarters project due to changes in investment conditions [9] Group 6 - Juguang Technology announced plans for shareholders to reduce their stakes by up to 2.33% of the company's total shares [10] - Yatai Group intends to sell a 20.81% stake in Northeast Securities, with the transaction subject to uncertainties [11] - Warner Pharmaceuticals reported a 46.95% increase in net profit for 2025, reaching 241 million yuan [12] - Lianrui New Materials achieved a 16.42% increase in net profit for 2025, totaling 293 million yuan [14] - Huayin Technology expects a 24.28% decrease in net profit for 2025, projecting 313 million yuan [15] - Ruijun New Materials reported a 23.48% increase in net profit for 2025, amounting to 311 million yuan [16] - Qizheng Tibetan Medicine's net profit grew by 10.98% in 2025, reaching 646 million yuan [17]

Group 1 - The company, Qizheng Tibetan Medicine, announced that it expects to achieve an operating revenue of 2,416.01 million yuan in 2025, representing a year-on-year growth of 3.34% [2] - The net profit attributable to shareholders of the listed company is projected to be 646.23 million yuan, reflecting a year-on-year increase of 10.98% [2]

Core Viewpoint - Chengdu-based innovative pharmaceutical leader Baillie Tianheng (688506.SH) is continuing its efforts to list H-shares in Hong Kong, as indicated by the recent decision to extend the validity period of the relevant resolutions [1][5] Group 1: Company Developments - On February 10, 2026, Baillie Tianheng's first extraordinary general meeting approved the extension of the resolution's validity period for issuing H-shares and listing [1] - The company previously announced on November 12, 2025, that it would delay its global offering and would not proceed according to the prospectus, postponing its planned listing on November 17, 2025 [1][5] - The delay in the global offering does not impact the company's current business operations, and the company is carefully evaluating the timeline for the global offering and listing [5] Group 2: Historical Context - Baillie Tianheng submitted its H-share listing application to the Hong Kong Stock Exchange on July 10, 2024, and subsequently resubmitted the application on January 21, 2025, and September 29, 2025 [5] - The company published its H-share hearing materials on October 22, 2025, to provide relevant information to the Hong Kong public and qualified investors [5] - As of October 2025, Baillie Tianheng's actual controller and chairman, Zhu Yi, was reported to have a net worth of 115 billion yuan, marking a significant rise of 44 positions compared to 2024 [5]

Group 1 - The Ministry of Industry and Information Technology has announced the list of national-level green factories for 2025, with three companies from Tai'an High-tech Zone included, accounting for 25% of the city's total selections [1] - The national-level green factory is recognized as the highest honor in the field of green development in manufacturing, focusing on land efficiency, clean production, waste resource utilization, and low-carbon energy [1] - The first batch of municipal-level green manufacturing lists for 2026 has been released, with seven companies, including Shandong Jingwei Pharmaceutical Co., Ltd., approved as municipal-level green factories [1] Group 2 - Tai'an High-tech Zone is implementing multiple measures to support enterprises in achieving green upgrades, including policy promotion and enhancing application capabilities [2] - The zone is establishing a gradient cultivation database to guide enterprises in material preparation, indicator optimization, and application processes, aiming to improve the success rate of applications [2] - Future efforts will focus on deepening the construction of the green manufacturing system, expanding policy outreach, and increasing support for low-carbon development to create a new highland for regional green manufacturing [2]

Group 1 - The core product of the company, Isupreglutide α, has received acceptance for a new veterinary drug clinical trial application for treating pet diabetes by the Ministry of Agriculture and Rural Affairs, with Phase I clinical trials expected to start in Q1 2026 [1] - Following the announcement, the company's stock price saw a significant increase, with a reported rise of 2.83% over the last five trading days as of February 13, 2026, closing at 27.60 HKD [1] - Despite the recent uptick, the stock has experienced a decline of 10.91% over the past 20 trading days, indicating volatility in its performance [1] Group 2 - Recent trading activity shows fluctuations in southbound capital, with a single-day reduction of 20,140 shares on February 10, 2026, and a total net reduction of 85,200 shares over the last five trading days [1] - However, there has been an overall net increase of 168,100 shares held over the past 20 trading days, with current holdings at 3,060,800 shares, representing 0.72% of the issued ordinary shares [1] - On February 13, 2026, there was a total net inflow of 529,140 HKD, indicating active participation from retail investors [1]

Core Viewpoint - Fosun Pharma's subsidiary, GSK (Wuhan) Pharmaceutical Co., Ltd., has received acceptance for the drug registration application of Cisplatin Injection by the National Medical Products Administration, indicating progress in the company's drug development pipeline [1] Group 1: Drug Development - The drug, Cisplatin Injection, is self-developed by the company and is intended for the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer [1] - As of January 2026, the company's cumulative R&D investment in this drug is approximately RMB 4.69 million (unaudited) [1] Group 2: Market Potential - According to the latest data from IQVIA CHPA, the sales revenue of Cisplatin Injection in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be approximately RMB 165 million in 2024 [1]